Evaxion Biotech A/S’s (EVAX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $14.00 price target on the stock. HC Wainwright also issued estimates for Evaxion Biotech A/S’s FY2027 earnings at $0.12 EPS, FY2028 earnings at $0.05 EPS and FY2029 earnings at $0.09 EPS.

Separately, Lake Street Capital cut their target price on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th.

Evaxion Biotech A/S Price Performance

Shares of NASDAQ EVAX opened at $1.51 on Wednesday. The firm has a market capitalization of $1.77 million, a P/E ratio of -1.04 and a beta of -0.25. The firm’s 50-day moving average price is $2.30 and its 200-day moving average price is $6.80. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. Evaxion Biotech A/S has a 1-year low of $1.50 and a 1-year high of $22.05.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Tuesday, April 1st. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.19. The firm had revenue of $0.12 million for the quarter, compared to analyst estimates of $1.66 million. Equities research analysts anticipate that Evaxion Biotech A/S will post -0.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC acquired a new position in Evaxion Biotech A/S (NASDAQ:EVAX) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned about 2.98% of Evaxion Biotech A/S as of its most recent SEC filing. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.